Azelastine Monoproduct (Astelin) for Perennial Allergic Rhinitis: FDA Approval Status

Azelastine monoproduct, marketed under the brand name Astelin, is an antihistamine nasal spray approved by the U.S. Food and Drug Administration (FDA) for the treatment of perennial allergic rhinitis.

Perennial Allergic Rhinitis

Perennial allergic rhinitis is a type of allergic rhinitis characterized by year-round symptoms. It is caused by exposure to allergens that are present throughout the year, such as dust mites, pet dander, mold spores, and certain indoor allergens. Common symptoms of perennial allergic rhinitis include sneezing, runny or stuffy nose, nasal itching, and nasal congestion.

Azelastine Monoproduct (Astelin)

Azelastine is an antihistamine that works by blocking the effects of histamine, a chemical released during an allergic reaction. By inhibiting histamine's action, Azelastine helps alleviate allergy symptoms in the nasal passages.

FDA Approval

Astelin (Azelastine monoproduct) received FDA approval for the treatment of perennial allergic rhinitis. The FDA approval indicates that the drug has undergone rigorous evaluation and is considered safe and effective for its intended use in managing the symptoms of perennial allergic rhinitis.

It's important to note that drug approvals and status can change over time. For the most up-to-date information on Azelastine monoproduct (Astelin) and its approval status for perennial allergic rhinitis, it is best to consult official sources such as the FDA or speak with a healthcare professional.